A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential ...
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...
“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.” Glioblastoma cells can restrict the DNA-damaging ...
I. Platinum-based therapies induce DNA inter-strand crosslinks (ICLs), which exacerbate genomic instability and impede DNA replication. In BRCA1/2-deficient tumor cells, the repair of these DNA ...
The MarketWatch News Department was not involved in the creation of this content. Atrogi announces first subjects dosed in human trial for lead candidate ATR-258 -- First-in-class oral therapy ATR-258 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results